Cramp and spasm
Conditions
Interventions
The present study involves a clinical trial with 2 arms, employing double-blind blinding. Sixty patients will be randomly selected and assigned to form two groups, each comprising 30 individuals. The
C10.597.613.500
Sponsors
Associação de Combate ao Câncer de Goiás - ACCG
Associação de Combate ao Câncer de Goiás - ACCG
Eligibility
Inclusion criteria
Inclusion criteria: Patients of both genders; with Chemotherapy-Induced Peripheral Neuropathy (CIPN); and/or treatments causing an excess of ions in the muscles and abrupt changes in pH
Exclusion criteria
Exclusion criteria: Cramps related to the sciatic nerve; or a previous history of cramps; or weak and intermittent cramps
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: Evaluate reduction of cramps in patients affected by chemotherapy-induced peripheral neuropathy, using Magicramp® technology, which is an electrostatic charge-reducing cushion ;Expected Encontrado 1: Improved pain and cramps caused by Chemotherapy-Induced Peripheral Neuropathy (CIPN), using Magicramp® technology, which is an electrostatic charge-reducing cushion | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected Outcome 2: We investigated the type of pain associated with cramps induced by chemotherapy drugs, aiming to distinguish it from various other causative sources and to elucidate mechanisms similar and dissimilar to this symptom, which has been classified as a disease by ICD-10 with codes 67.2 (cramps due to heat) and 25.2. This was done to enable the physician to differentiate the diagnosis and find the most specific solution possible. However, we did not obtain clear results because the medical records presented a variety of medications. Additionally, each participant cited many types of pain in the McGill questionnaire, and due to the small sample size with various interventions, we did not have an adequate numerical basis to establish correlations;Outcome found 2: We did not obtain clear results regarding pain/medication distinction, due to Hospital Araujo Jorge being filled with medication innovations, with many clinical trials using new drugs, and medical records presenting a high variety of new oncology medications. It was not possible to establish causal relationships. Additionally, each participant mentioned multiple types of pain from the extensive MCGILL questionnaire used, and therefore, the 29 patients with various different interventions did not provide us with an adequate numerical basis to correlate types of pain with their specific medications | — |
Countries
Brazil
Contacts
Public ContactGeraldo Queiroz
Associação de Combate ao Câncer de Goiás - ACCG
Outcome results
None listed